Exon skipping compositions for treating muscular dystrophy
US-9217148-B2 · Dec 22, 2015 · US
US9795683B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9795683-B2 |
| Application number | US-84328410-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 26, 2010 |
| Priority date | Jul 27, 2009 |
| Publication date | Oct 24, 2017 |
| Grant date | Oct 24, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A water soluble polymer, in particular polysialic acid (PSA) or a modified PSA (mPSA), is conjugated to an oxidized carbohydrate moiety of a glycoprotein other than a blood coagulation protein or to a ganglioside or drug delivery system by contacting the oxidized carbohydrate moiety with the water soluble polymer, wherein said water soluble polymer contains an aminooxy group and an oxime linkage is formed between the oxidized carbohydrate moiety and the aminooxy group on the water soluble polymer or wherein said water soluble polymer contains a hydrazide group and a hydrazone linkage is formed between the oxidized carbohydrate moiety and the hydrazide group on the water soluble polymer. Conjugates of aminooxy- or hydrazide-water soluble polymer, such as PSA and mPSA, are thus obtained in which the PSA or mPSA is attached via a carbohydrate moiety.
Opening claim text (preview).
The invention claimed is: 1. A method of conjugating a polysialic acid (PSA) or a modified PSA (mPSA) to an oxidized carbohydrate moiety on a polypeptide with DNase activity, comprising contacting the oxidized carbohydrate moiety with the PSA or mPSA under conditions that allow conjugation, wherein said PSA or mPSA contains an aminooxy group and an oxime linkage is formed between the oxidized carbohydrate moiety and the aminooxy group on the PSA or mPSA; and wherein said polypeptide has a specific activity of at least 80% relative to an unmodified polypeptide. 2. The method of claim 1 wherein the PSA or mPSA is colominic acid or modified colominic acid. 3. The method of claim 1 wherein the PSA or mPSA comprises 10-300 sialic acid units. 4. The method of claim 1 , further comprising oxidizing the carbohydrate moiety by incubating said polypeptide with sodium periodate (NaIO 4 ). 5. The method of claim 1 , further comprising oxidizing the PSA or mPSA to form an aldehyde group on a terminal unit of the PSA or mPSA, and reacting the oxidized PSA or mPSA with an aminooxy linker. 6. The method of claim 5 comprising oxidizing the PSA or mPSA using NaIO 4 . 7. The method of claim 1 wherein said contacting the oxidized carbohydrate moiety with PSA or mPSA occurs in a buffer comprising a nucleophilic catalyst selected from the group consisting of aniline and aniline derivatives. 8. The method of claim 1 wherein the aminooxy group is formed by reacting oxidized PSA or mPSA with an aminooxy linker selected from the group consisting of 3- oxa-pentane-1,5 -dioxyamine and 3,6, 9-trioxa-undecane-1, 11-dioxyamine. 9. The method of claim 1 further comprising reducing an oxime linkage said polypeptide by incubation in the presence of a reducing compound. 10. The method according to claim 9 wherein the reducing compound is sodium cyanoborohydride (NaCNBH 3 ) or ascorbic acid (vitamin C). 11. A conjugated polypeptide with DNase activity, comprising: (a) a polypeptide with DNase activity; and (b) at least one aminooxy-PSA or aminooxy-mPSA bound to the polypeptide of (a), wherein said aminooxy-PSA or aminooxy-mPSA is attached to the polypeptide via one or more oxidized carbohydrate moieties; and wherein said polypeptide has a specific activity of at least 80% relative to an unmodified polypeptide.
Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers · CPC title
Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids · CPC title
the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title
Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047) · CPC title
the organic macromolecular compound being a polysaccharide or a derivative thereof · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.